SuperBowl Breast Cancer Cure In The Red Zone --- Close To A Successful Touch Down

February 3, 2013 By Barrons Medical Journal Reporting ---- New Orleans NFL Super Bowl Week -----< Business--Wire>

---

---

Barron Medical Journal 3rd Annual Super Bowl Breast Cancer Report:

---

Breast Cancer Cure In The Red Zone --- Close To A Successful Touch Down

---

New Orleans ( AP ) Approximately 30% of malignant breast cancers demonstrate

overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based chemotherapy.

The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Gennxeix Biotech Inc Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. One of the major player and touch down makers for breast cancer is Houston Texas Methodist Hospital. In A clinical Trial A Rev. Noel Denison, a retired Methodist minister, was diagnosed with locally advanced HER2-positive breast cancer and is enrolled in the study at Methodist, one of only two locations in the United States. The clinical trial is for locally advanced or metastatic HER2-positive breast cancer and combines standard chemotherapy with trastuzumab emtansine, better known in the breast cancer world as T-DM1, and pertuzumab, a monoclonal antibody that also attaches to HER2 on cancer cells. Using Genomics and semiconductors to detect breast cancer plus T-DM1 to treat breast

cancer is a winning combination. What is T-DM1? T-DM1 is in a new class of cancer-fighting agents called antibody drug conjugates. By combining the antibody trastuzumab directly with docetaxel (standard chemotherapy) and/or pertuzumab, the T-DMI is designed to attack the tumor cells directly and deliver the chemotherapy. Trastuzumab emtansine (T-DM1) consists of our proprietary DM1 cancer-killing agent attached to the HER2-binding antibody, trastuzumab, developed by Genentech (a member of the Roche Group) using our linker and methods of attachment. Trastuzumab emtansine is in global development by Roche under a collaboration agreement between ImmunoGen and Genentech. Marketing applications for trastuzumab emtansine are under review in the US and Europe. The Defense and the most dangerous aspect of breast cancer is its ability to spread to distant sites, most tumors are initially unable to do that Learning more specifically what triggers metastases may provide additional targets for preventing and treating the malignant process that causes cancer deaths. It’s widely accepted that cancers acquire the ability to spread through the gradual accumulation of genetic changes, and experiments have also shown that these changes occur in parallel with changes in the protein content and 3-dimensional patterning of the protein meshwork that creates their immediate surroundings Gene that stops the growth of KCNK9 Genes is gene is p53. p53 is a fundamental determinant of cancer susceptibility, p53 integrates stress signals and elicits apoplectic responses that maintain genomic stability. When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses

and which has a major role in the cell responses to these stresses. This process is why it is important Conrad says for people that are first degree relatives of breast cancer patients, must take a genomic test to see if they are the carrier of gene KCNK9. By identifying this gene we can direct patients with the correct advise as to deal with the fact that they have a lunp on the breast to they are going to get a lump on their breast. Often what happens is that a breast cancer patients dose not go to the doctor or take important test to see if there is a lump on the breast. what happens is the spread of breast cancer is responsible for more than 90 percent of breast cancer deaths.

Super Bowl Week In New Orleans 2013 will see a Touch down and a Championship in a breast cancer cure before the end of President Obama 2nd Term

The Blue Print To Prevent Breast Cancer - Has A New Tool " Big Data"

Barrons Medical Journal Reporting From President Barack Obama Inauguration 2013 George Washington University Medical Center, Washington DC, United States.

---

The Blue Print To Prevent Breast Cancer - Has A New Tool " Big Data"

---

The blueprint to prevent breast cancer from invading your body is now the focus of several science organization in the United States. The new tool is called Big Data. At the JP Morgan Health Care conference Big Data dominated the sessions. Pharmaceuticals companies are taking notice and Houston Texas based Biotech Company Gennxeix Biotech Software has created the Blue Print. Let start with the understanding of Big Data.

---

Brought To You By: Zoya Tommy Contemporary Art Gallery: is pleased to announce the opening of Horizontal by Frank X Tolbert2 on January 26, 2013 at 6:00pm. The show will run through February 23, 2013

---

Modern science business intelligence methods allow analysts to drill down into complex gene databases and find the answers to predetermined questions, but the emergent field of data science is concerned with finding the questions that should

be asked of huge and often unstructured data in order to yield otherwise invisible results, such as what can stop breast cancer cells from reprogramming their metabolic pathways to meet their abnormal demands for proliferation and survival that causes oncogenes to create breast cancer Tumors. It has long been recognized that cancer cells need a higher rate of metabolism to support their accelerated proliferation and growth rate. The most known metabolic change is a phenomenon called “Warburg effect” first described by Otto Warburg in 1920s. Warburg reported that breast cancer cells take up and utilize much more glucose for glycolysis compared to normal cells, even in the normoxic condition Using Big Data Technology , data scientists at Gennxeix Biotech can run algorithms that carry out what is effectively blind analysis of a gene database to reveal the inherent patterns therein, rather than showing correlations between preselected variables. By being able to identifying the cocktail of genes that cause breast cancer we can create therapies or some would say Medicines to stop the Breast Cancer Disease from happening

Genomics Science allows big data today to ask the right questions of the gene data. The power Gennomics Biotech Software is its unique ability to automatically discover insights without asking questions. With this powerful Analytics Tools Scientist and Doctors can predict and pinpoint to when the breast cancer is going to enter the breast. There are increasing evidences to support that oncoproteins directly reprogram the metabolism of breast cancer cells, and make them addict to certain metabolic pathways. Therefore, the signaling pathways controlling the altered metabolism in breast cancer cells are attractive targets for cancer therapy. Like the Warburg effect, alteration of lipid metabolism is another nearly ubiquitous change in tumor cells. lipid metabolism in breast cancer cells. The increased de novo lipogenesis in breast cancer cells a major cause for all concerned in creating a breast cancer prevention model. Genomics has yielded unprecedented results in the breast cancer, Comparative big data gene-expression analyses on primary breast tumors and lymph node metastases have indicated that, metastases have very similar expression signatures compared with their parent tumors. Detailed analyses have also revealed that a number of genes are consistently differentially expressed between primary tumors and metastases and that metastases often show a greater variety of aberrations than the

primary tumor. At the chromosomal level, even greater differences have been described between primary breast tumors and their derived metastases. dose exist. In general, all of these studies showed that metastases harbor more and also new aberrations that could not be found in the corresponding primary tumors. These results imply that the clonal evolution of a tumor is more complex than would be predicted by linear models, highlighting the importance of investigating distant metastases as the end point of the metastatic cascade. Obesity is associated with increased breast cancer risk, especially among postmenopausal women. Alcohol shows an increased risk of breast cancer associated with alcohol consumption. The inherited genetic profile of an individual influences susceptibility to mutagens and growth factors, which initiate or promote the carcinogenic process. Known genetic syndromes in breast cancers. With Genomics and Big Data we are in the Breast cancer cure red zone :

How Dose That Lump Get On To Your Breast And Where Dose That Tumor Come From

Barron Medical Journal Reporting From Washington DC Georgetown Hospital In The Georgetown section of Washington DC:

---

How Dose That Lump Get On To Your Breast And Where Dose That Tumor Come From

---

Washington DC ( AP) Less than a Week from President Obama 2013 Inauguration It is Rumored that a breast cancer cure is going to take place before the end of the 2nd Term of President Obama: What A Great Legacy that would be. To honor the Inauguration Barron's Medical Journal Interviewed Rose Conrad M.D., Ph.D. The CEO of

Gennxeix Biotech Inc and ask the question: How dose that lump get on to your breast and where dose that lump come from ? Conrad responded with a smile on her face and said let's open up the breast cancer playbook. Oncogene are genes that take your genes and DNA and convert the your genes to breast cancer genes. The most known gene associated with breast cancer is the KCNK9 Gene. KCNK9 encodes a potassium channel that allows the breast cancer tumor to grow on your breast. This process is aided by Hypoxia. Hypoxia refers to an inadequate oxygen supply to the cells and tissues of the Breast.

---

Brought To You By: Zoya Tommy Contemporary Art Gallery: is pleased to announce the opening of Horizontal by Frank X Tolbert2 on January 26, 2013 at 6:00pm. The show will run through February 23, 2013

---

The Main Gene that stops the growth of KCNK9 Genes is gene is p53. p53 is a fundamental determinant of cancer susceptibility, p53 integrates stress signals and elicits apoplectic responses that maintain genomic stability. When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses and which has a major role in the cell responses to these stresses. This process is why it is important Conrad says for people that are first degree relatives of breast cancer patients, must take

a genomic test to see if they are the carrier of gene KCNK9. By identifying this gene we can direct patients with the correct advise as to deal with the fact that they have a lunp on the breast to they are going to get a lump on their breast. Often what happens is that a breast cancer patients dose not go to the doctor or take important test to see if there is a lump on the breast. what happens is the spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. The process by which breast cancer spreads -- or metastasizes is where Metastasis was long thought as a late event in breast cancer progression, With Genomics we now shown metastasis to be an early event that is dependent on Hypoxia HIF-1. HIF-1 protein controls genes that enable cells to survive in low oxygen, like cells in solid breast tumors. In order for breast cancer cells to spread to lungs, they must leave the breast,enter blood vessels that lead to the lungs, and exit those same vessels. "

Blood vessels are pretty tight; a cell has to work pretty hard to get through the vessel wall. How this process works is breast cancer cells turn on genes called ANGPTL4, ANGPTL4, helps breast cancer to travel through blood vessel walls. Research is now being performed with Genomics. The Gennxeix Biotech Team found by injecting these cells either with normal or "knocked-down" levels of ANGPTL4 into mice and examining their lungs. Cells lacking HIF-1 and containing extra ANGPTL4 were better able to invade the lungs than cells without extra ANGPTL4. There are other genes that are involved in the creation of a breast cancer tumor on the breast. Her-2, p63, 73. Conrad goes on to say that in their genomic test uses 21 different genes to project ,stop the growth and the spread of a patients breast cancer Lump. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of VEGF expression. GenNXeix demonstrate that HER2 signaling induced by over expression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (KBPS-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1 treatments


Houston’s Science and Medicine Communities love Supporting The Arts and Sports

Barron’s Medical Journal Reporting From Houston Texas Museum District, Galleria, And Reliant Park Houston:

---

Houston ( AP ) Diamond in Your Life Report: Houston’s Science and Medicine Communities love Supporting The Arts and Sports.

---

Houston ( AP ) Diamond in Your Life Report: Barron’s Medical Journal has known for a long time that the folks that work in science and medicine love supporting the arts and sports. One city that has it all is Houston Texas, Yes Houston has one of the great art scenes, with the Texans entering the playoffs for a second year and the Chevron Marathon Barron’s Medical Journal Diamond in Your Life Report: visited these hot spots in Houston.